Results 61 to 70 of about 82,921 (179)

Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia

Haematologica, 2020
Antibodies against polyethylene glycol (PEG) in healthy subjects raise concerns about the efficacy of pegylated drugs. We evaluated the prevalence of antibodies against PEG among patients with acute lymphoblastic leukemia (ALL) prior to and/or ...
Alaeddin Khalil, Gudrun Würthwein, Jana Golitsch, Georg Hempel, Manfred Fobker, Joachim Gerss, Anja Möricke, Martin Zimmermann, Petr Smisek, Massimo Zucchetti, Christa Nath, Andishe Attarbaschi, Arend von Stackelberg, Nicola Gökbuget, Carmelo Rizzari, Valentino Conter, Martin Schrappe, Joachim Boos, Claudia Lanvers-Kaminsky   +18 more
doaj   +1 more source

Genetic Determinants of Treatment‐Related Bone Toxicity in Pediatric Acute Lymphoblastic Leukemia

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 786-794, September 2026.
Osteonecrosis and fractures are serious corticosteroid‐induced bone toxicities in children treated for acute lymphoblastic leukemia, yet their genetic determinants remain incompletely defined. In this study, we aimed to identify novel genetic contributors to bone toxicity and to evaluate the robustness of both newly identified and previously ...
Rachid Abaji, Vincent Gagné, Émilie Espagne, Nathalie Alos, Veronica Del Vecchio, Lamia Ait Said, Albert Shalmiev, Claire Fuchs, Caroline Laverdière, Jean‐Marie Leclerc, Stephen E. Sallan, Lewis B. Silverman, Daniel Sinnett, Thai Hoa Tran, Maja Krajinovic   +14 more
wiley   +1 more source

Premedication Prior to Peg-Asparaginase Is Cost-Effective for Pediatric Leukemia Patients

Blood, 2020
Background: Asparaginase is a critical therapy component for childhood acute lymphoblastic leukemia (ALL). Hypersensitivity reactions and silent inactivation by neutralizing antibodies can lead to withholding further doses. Reactions occur in 10-20% of children receiving the commonly used, widely available pegylated asparaginase.
Meghan McCormick, Jillian Lapinski, Erika Friehling, Ken Smith   +3 more
openaire   +1 more source

Optimizing safety and efficacy of asparaginase and blinatumomab therapy in frontline acute lymphoblastic leukemia regimens in diverse health care settings—international expert consensus

Cancer, Volume 132, Issue 16, 15 August 2026.
ABSTRACT Frontline blinatumomab combined with chemotherapy has resulted in improved outcomes in both pediatric and adult patients with acute lymphoblastic leukemia and is considered the new cornerstone of acute lymphoblastic leukemia treatment. The role of asparaginase in this new landscape of acute lymphoblastic leukemia treatment was extensively ...
Daniel J. DeAngelo, Anna Avagyan, Jeanine Alfaro, Valentino Conter, Maria L. de Martino Lee, Łukasz Hutnik, Miriam Hwang, Hiroto Inaba, Atsushi Manabe, Jae H. Park, Rob Pieters, Carmelo Rizzari, Vaskar Saha, David T. Teachey, Inge M. van der Sluis, Scott C. Howard   +15 more
wiley   +1 more source

Hypersensitivity to Excipients in Drugs: An EAACI Position Paper

Allergy, Volume 81, Issue 7, Page 2250-2275, July 2026.
ABSTRACT Drugs contain active pharmaceutical ingredients and excipients, compounds which enhance the pharmacokinetics, stability and palatability of the pharmaceutical formulation. While most drug hypersensitivity reactions (DHR) are caused by active ingredients, excipients may also be involved.
Lene H. Garvey, Knut Brockow, Annick Barbaud, Charlotte G. Mortz, Gianfranco Calogiuri, Asli Gelincik, Osman O. Yeğit, Alla Nakonechna, Annette Wagner, Rik Schrijvers, Toon Ieven   +10 more
wiley   +1 more source

Ph‐Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs

European Journal of Haematology, Volume 117, Issue 1, Page 24-41, July 2026.
ABSTRACT Acute lymphoblastic leukaemia (ALL) in older adults represents a growing clinical challenge, driven by an ageing population, adverse disease biology, and reduced tolerance to intensive chemotherapy. Although pediatric‐inspired regimens have improved outcomes in younger adults with Philadelphia chromosome (Ph)‐negative ALL, survival in older ...
Antonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, Santino Caserta, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Marco Fiorillo, Nicola Amodio, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Dexamethasone and asparaginase treatment regimens. [PDF]

, 2016
Horizontal arrows represent dexamethasone treatment (2 or 4 mg/L in drinking water) and vertical arrows represent PEG-asparaginase (Oncaspar) treatment (1200 or 1500 IU/kg twice weekly via i.p. injection).
Xiangjun Cai (780959), Leonard A. Mattano Jr. (3181083), Mary V. Relling (47096), Kelli L. Boyd (245348), Amy J. Funk (3181086), Jitesh D. Kawedia (384551), Chengcheng Liu (402506), Laura J. Janke (780957), Laura B. Ramsey (780956)   +8 more
core   +1 more source

Breakthrough reactions in pediatric chemotherapeutic desensitization: Outcomes and associated risk factors

Pediatric Allergy and Immunology, Volume 37, Issue 7, July 2026.
Breakthrough reactions in Pediatric chemotherapeutic desensitization: outcomes and associated risk factors. Abstract Background Rapid drug desensitization (RDD) enables the safe reintroduction of chemotherapeutic agents in patients with hypersensitivity reactions (HSRs).
Pathitta Doradee, Supaluk Tangvalelerd, Kantima Kanchanapoomi, Prapasri Kulalert, Punchama Pacharn, Orathai Jirapongsananuruk, Witchaya Srisuwatchari   +6 more
wiley   +1 more source

Retrospective post-marketing study on the use of bio-similar pegasparagase among acute lymphoblastic leukemia patients in India

Pediatric Hematology Oncology Journal, 2018
Background: Acute lymphoblastic leukemia (ALL) is a cancer of lymphoid progenitor cells with highest incidence among children aged 2–3 years. Pegaspargase, the PEGylated form of L-asparaginase (PEG-ASP) is a component of multidrug regimens used in the ...
Anil Kamat
doaj   +1 more source

Artificial Cells: Perspective on Reconstructing Biological Cells and “Out of the Box” Innovations

ChemBioChem, Volume 27, Issue 12, 26 June 2026.
The first artificial cell was artificial red blood cells (RBCs) (Chang, 1957), RBC is one of the most important cells because our cells, tissues, organs, and whole human being need it for survival. Even more exciting is innovating this to result in artificial cells of unlimited configurations, contents, and applications.
Thomas Ming Swi Chang
wiley   +1 more source